The medicine, Blincyto, contains Blinatumomab as an active ingredient with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells). The drug Blinatumomab is produced in Chinese hamster ovary cells. The medicine Blincyto is supplied in a single-dose vial as a sterile, preservative-free, white to off-white lyophilized powder for intravenous administration in the strength of 35 mcg. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, the release of inflammatory cytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells. This drug is used in the treatment of patients who have relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Blincyto price is reasonable in India, and it is easily available from certified suppliers of generic medicines. Indian Pharma Network is a certified generic medicine supplier, supplying medicines all over the world for more than 7 years.
Blinatumomab: Single-dose vial
The medicine Blincyto is used by healthcare professionals to treat This drug is used to treat patients who have relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blincyto contains Blinatumomab, a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. This medicine is produced in Chinese hamster ovary cells. Blinatumomab comes in the strength of 35 mcg in single-dose vials for intravenous infusion. The active ingredient in the vials is Blinatumomab and monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide are the inactive ingredients. The general recommended dosage of Blinatumomab is based on the prescribed doses.
Blinatumomab 35 mcg is readily available with various generic medicine suppliers. If you want detailed information on Blincyto, contact us on 18008891064.
Blinatumomab: An FDA approved drug
The FDA approved the drug Blinatumomab in 2014 to treat patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells). The drug Blinatumomab is produced in Chinese hamster ovary cells. The trade name for Blinatumomab is Blincyto, and it is supplied in the form of single-dose vials in 35 mcg to administer intravenously. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin, and CD3 expressed on the surface of T cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B cells. Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle.
Blinatumomab injection is readily available from several generic medicine suppliers in India; for more information about this drug, call us toll-free no. 18008891064.
